Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.995 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	3.995
Bid (Size)	3.600 (500)
Ask (Size)	6.300 (1,800)
Prev. Close	3.995
Today's Range	3.995 - 3.995
52wk Range	3.750 - 13.50
Shares Outstanding	128,404,735
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses ↗

August 19, 2026

Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses...

Via MarketBeat

Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS ↗

August 12, 2026

Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of...

Via MarketBeat

Performance

YTD	-30.8%	-30.8%
1 Month	-24.3%	-24.3%
3 Month	-31.4%	-31.4%
6 Month	-24.6%	-24.6%
1 Year	-28.5%	-28.5%

More News

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 22, 2026

Via Investor Brand Network

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026

From BioMedWire

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 31, 2025

Via Benzinga

Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis

September 26, 2025

Via Investor Brand Network

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025

September 25, 2025

Via Investor Brand Network

New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease

September 16, 2025

Via Investor Brand Network

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

September 16, 2025

Via Investor Brand Network

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

September 09, 2025

Via Investor Brand Network

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model

September 04, 2025

Via Investor Brand Network

Research Uncovers Possible Way to Repair Myelin in MS Patients

September 04, 2025

Via Investor Brand Network

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference

September 02, 2025

Via Investor Brand Network

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline

August 29, 2025

Via Investor Brand Network

Pioneering Therapy Could Slow the Effects of Aging

August 22, 2025

Via Investor Brand Network

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

August 21, 2025

Via Investor Brand Network

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy

August 14, 2025

Via Investor Brand Network

Clene Posts 70% Revenue Drop in Q2 ↗

August 14, 2025

Via The Motley Fool

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20

August 13, 2025

Via Investor Brand Network

Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option

August 12, 2025

Via Investor Brand Network

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference

August 05, 2025

Via Investor Brand Network

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

July 31, 2025

Via Investor Brand Network

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

July 28, 2025

Via Investor Brand Network

Frequently Asked Questions

Is Clene Inc. - Common Stock publicly traded?

Yes, Clene Inc. - Common Stock is publicly traded.

What exchange does Clene Inc. - Common Stock trade on?

Clene Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Clene Inc. - Common Stock?

The ticker symbol for Clene Inc. - Common Stock is CLNN on the Nasdaq Stock Market

What is the current price of Clene Inc. - Common Stock?

The current price of Clene Inc. - Common Stock is 3.995

When was Clene Inc. - Common Stock last traded?

The last trade of Clene Inc. - Common Stock was at 09/03/26 04:00 PM ET

What is the market capitalization of Clene Inc. - Common Stock?

The market capitalization of Clene Inc. - Common Stock is 512.98M

How many shares of Clene Inc. - Common Stock are outstanding?

Clene Inc. - Common Stock has 513M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.